Clade Therapeutics Inc.
Total Consideration
$39.7M
Share price: $4.05
Purchase-Price Allocation
Goodwill
$4.3M
Intangibles
$34.2M
Liabilities Assumed
$15.2M
Contingent Earn-Out
$10.0M
Deferred Tax Liability
$3.5M
Century Therapeutics, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$2
Free Cash Flow Per Share
$-1
Cash Per Share
$1
Revenue Per Share
$1
OCF Per Share
$-1
Return on Equity
-6.0%
Return on Assets
-3.3%
Return on Invested Capital
-8.5%
Debt to Equity
—
Current Ratio
5.97
Quick Ratio
5.97
Asset Turnover
0.38
R&D / Revenue
87.6%
SBC / Revenue
6.3%
Capex / Revenue
0.8%
Working Capital
$101M
Net Current Asset Value
$56M
Invested Capital
$159M
OCF / Net Income
10.84
FCF / Net Income
10.93
Accruals Ratio (Sloan)
42.2%
Net Debt
$-117M
Net Debt / EBITDA
28.10
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-122.50
Tangible Common Equity
$125M
TCE / Total Assets
55.8%
NOPAT
$-14M
Cash ROIC
-65.4%
WC / Revenue
92.1%
Capex / D&A
0.06
Reinvestment Rate
71.0%
Asset Growth vs Revenue Growth
-1593.4%
Stock Price (FY-end)
$1
Market Cap
$86M
P/S Ratio
0.79
P/B Ratio
0.54
P/TB Ratio
0.69
P/OCF Ratio
—
Enterprise Value
$-31M
EV / Sales
-0.28
FCF Yield
-121.6%
Shareholder Yield
-7.9%
R&D Yield
111.1%
Capex Yield
1.0%
Shares Variation (YoY)
10.1%
Beta (5Y)
1.31
Cost of Equity
11.0%
Cost of Debt (after tax)
—
52W High
$1
52W Low
$0
Trailing Return 1Y
-4.3%
F-Score (Piotroski)
3.00
Z-Score (Altman)
-3.39
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Stock Price on Earnings Dates
Century Therapeutics, Inc. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | 10.50% | 11.00% | 8.70% | -1.10% | 0.80% |
| Foreign Rate Differential | — | — | 0.00% | 0.00% | 0.10% | 0.10% |
| Other Adjustments | — | -3.00% | -0.70% | 1.60% | -0.60% | — |
| R&D Tax Credits | — | — | — | — | -2.90% | -47.60% |
| SBC (Nondeductible) | — | — | — | — | 0.10% | -0.20% |
| Valuation Allowance Change | — | -32.20% | -33.80% | -36.30% | -22.50% | -73.80% |
| Tax Law Change | — | -0.70% | 0.00% | 0.00% | 0.00% | — |
| Effective Tax Rate | — | -0.10% | 0.00% | -1.30% | -1.50% | 0.70% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | — | $43.0K | $91.0K | $1.9M | $1.8M | −$68.0K |
| Income Taxes Paid (Cash) | — | — | — | — | $507.0K | — |
Century Therapeutics, Inc. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.